Switch to:
Also traded in: Brazil, Germany, Mexico, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.04
TMO's Cash-to-Debt is ranked lower than
96% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. TMO: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
TMO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.41 Max: N/A
Current: 0.04
Equity-to-Asset 0.47
TMO's Equity-to-Asset is ranked lower than
66% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TMO: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
TMO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.75
Current: 0.47
0.31
0.75
Interest Coverage 5.12
TMO's Interest Coverage is ranked lower than
81% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. TMO: 5.12 )
Ranked among companies with meaningful Interest Coverage only.
TMO' s Interest Coverage Range Over the Past 10 Years
Min: 5.12  Med: 6.56 Max: 14.24
Current: 5.12
5.12
14.24
Piotroski F-Score: 8
Altman Z-Score: 2.23
Beneish M-Score: -2.47
WACC vs ROIC
7.42%
7.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 13.62
TMO's Operating Margin % is ranked higher than
77% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. TMO: 13.62 )
Ranked among companies with meaningful Operating Margin % only.
TMO' s Operating Margin % Range Over the Past 10 Years
Min: 10  Med: 11.78 Max: 14.82
Current: 13.62
10
14.82
Net Margin % 11.58
TMO's Net Margin % is ranked higher than
84% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. TMO: 11.58 )
Ranked among companies with meaningful Net Margin % only.
TMO' s Net Margin % Range Over the Past 10 Years
Min: 7.81  Med: 9.77 Max: 11.64
Current: 11.58
7.81
11.64
ROE % 10.13
TMO's ROE % is ranked higher than
63% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. TMO: 10.13 )
Ranked among companies with meaningful ROE % only.
TMO' s ROE % Range Over the Past 10 Years
Min: 5.36  Med: 7.8 Max: 10.13
Current: 10.13
5.36
10.13
ROA % 4.82
TMO's ROA % is ranked higher than
66% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. TMO: 4.82 )
Ranked among companies with meaningful ROA % only.
TMO' s ROA % Range Over the Past 10 Years
Min: 3.58  Med: 4.65 Max: 5.52
Current: 4.82
3.58
5.52
ROC (Joel Greenblatt) % 48.58
TMO's ROC (Joel Greenblatt) % is ranked higher than
80% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. TMO: 48.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TMO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 37.47  Med: 42.04 Max: 62.88
Current: 48.58
37.47
62.88
3-Year Revenue Growth Rate 8.70
TMO's 3-Year Revenue Growth Rate is ranked higher than
63% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. TMO: 8.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TMO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.9  Med: 7.3 Max: 18.7
Current: 8.7
-12.9
18.7
3-Year EBITDA Growth Rate 14.90
TMO's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. TMO: 14.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TMO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -30.1  Med: 14.9 Max: 40.9
Current: 14.9
-30.1
40.9
3-Year EPS without NRI Growth Rate 13.40
TMO's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. TMO: 13.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TMO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -43.5  Med: 14 Max: 74.6
Current: 13.4
-43.5
74.6
GuruFocus has detected 5 Warning Signs with Thermo Fisher Scientific Inc $TMO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TMO's 10-Y Financials

Financials (Next Earnings Date: 2017-05-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

TMO Guru Trades in Q2 2016

Ray Dalio 12,466 sh (New)
Paul Tudor Jones 3,600 sh (New)
Pioneer Investments 2,593,804 sh (+10.20%)
Mairs and Power 1,786 sh (+6.12%)
First Pacific Advisors 1,788,830 sh (+5.91%)
Vanguard Health Care Fund 4,315,800 sh (unchged)
First Eagle Investment 200 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 141,000 sh (unchged)
Ken Fisher Sold Out
Scott Black Sold Out
Mario Gabelli 32,545 sh (-0.53%)
John Rogers 536,549 sh (-0.64%)
Diamond Hill Capital 574,065 sh (-1.18%)
PRIMECAP Management 5,362,400 sh (-1.41%)
David Dreman 9,811 sh (-3.22%)
Dodge & Cox 526,642 sh (-4.40%)
Steven Romick 1,415,820 sh (-6.10%)
Manning & Napier Advisors, Inc 631,340 sh (-8.22%)
Larry Robbins 2,858,240 sh (-20.84%)
Joel Greenblatt 1,790 sh (-61.81%)
» More
Q3 2016

TMO Guru Trades in Q3 2016

Ken Fisher 1,482 sh (New)
Pioneer Investments 2,645,237 sh (+1.98%)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (+64.08%)
First Eagle Investment 200 sh (unchged)
Joel Greenblatt Sold Out
John Rogers 526,143 sh (-1.94%)
PRIMECAP Management 5,204,870 sh (-2.94%)
Diamond Hill Capital 551,677 sh (-3.90%)
David Dreman 9,343 sh (-4.77%)
Vanguard Health Care Fund 4,097,300 sh (-5.06%)
Mairs and Power 1,683 sh (-5.77%)
Larry Robbins 2,686,316 sh (-6.02%)
First Pacific Advisors 1,676,150 sh (-6.30%)
Steven Romick 1,306,510 sh (-7.72%)
Ray Dalio 10,600 sh (-14.97%)
Mario Gabelli 27,345 sh (-15.98%)
Signature Select Canadian Fund 72,350 sh (-16.07%)
Paul Tudor Jones 3,000 sh (-16.67%)
Manning & Napier Advisors, Inc 413,541 sh (-34.50%)
Dodge & Cox 67,602 sh (-87.16%)
» More
Q4 2016

TMO Guru Trades in Q4 2016

Jim Simons 813,644 sh (New)
Wallace Weitz 132,160 sh (New)
Steven Cohen 183,552 sh (New)
Caxton Associates 40,000 sh (New)
Ray Dalio 28,700 sh (+170.75%)
Larry Robbins 3,659,734 sh (+36.24%)
Diamond Hill Capital 647,502 sh (+17.37%)
Ken Fisher 1,707 sh (+15.18%)
Mario Gabelli 29,220 sh (+6.86%)
PRIMECAP Management 5,304,730 sh (+1.92%)
Manning & Napier Advisors, Inc 415,211 sh (+0.40%)
First Eagle Investment 200 sh (unchged)
Mairs and Power 1,683 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 231,352 sh (unchged)
David Dreman 8,862 sh (-5.15%)
Vanguard Health Care Fund 3,884,800 sh (-5.19%)
John Rogers 483,526 sh (-8.10%)
First Pacific Advisors 1,460,100 sh (-12.89%)
Steven Romick 1,134,900 sh (-13.13%)
Paul Tudor Jones 2,500 sh (-16.67%)
Pioneer Investments 2,185,073 sh (-17.40%)
Dodge & Cox 50,002 sh (-26.03%)
» More
Q1 2017

TMO Guru Trades in Q1 2017

Ken Fisher 2,602 sh (+52.43%)
Steven Romick 1,134,900 sh (unchged)
Manning & Napier Advisors, Inc 327,503 sh (-21.12%)
» More
» Details

Insider Trades

Latest Guru Trades with TMO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541380    SIC: 3826
Compare:NYSE:DHR, NYSE:Q, NYSE:A, NAS:IDXX, NYSE:DGX, NYSE:LH, OTCPK:SSMXY, OTCPK:ERFSF, OTCPK:BMXMF, NAS:QGEN, NAS:DXCM, NYSE:PKI, NYSE:BIO.B, NAS:INCR, NAS:ICLR, NYSE:ALR, NYSE:CRL, OTCPK:SWTUY, OTCPK:DSRLF, NAS:PRAH » details
Traded in other countries:TMOS34.Brazil, TN8.Germany, TMO.Mexico, TFS.Switzerland,
Headquarter Location:USA
Thermo Fisher Scientific Inc offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs.

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments: analytical technologies (about 22% of sales after the FEI acquisition); specialty diagnostic products (18%); life science solutions (27% including Affymetrix); and lab products and services (37%).

Guru Investment Theses on Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific - Jan 26, 2017

Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

John Rogers Comments on Thermo Fisher Scientific Inc. - Jan 20, 2017

Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track.

From John Rogers (Trades, Portfolio)' Ariel Appreciation Fund fourth quarter 2016 commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about Thermo Fisher Scientific Inc

Weitz Funds Comments on Thermo Fisher Scientific Guru stock highlight
Thermo Fisher Scientific (NYSE:TMO) provides analytical instruments, equipment, reagents and consumables, as well as software and services for research, analysis, discovery and diagnostics across most of the globe. Thermo is well-diversified by both product and end market, boasting strong defensible market positions and reputable brands. Roughly three quarters of the company’s revenues are recurring in nature (consumables and services), consistent with our preference for subscription-like cash flow streams. Its portfolio of businesses is characterized by stable pricing, relatively acyclical organic growth and consistent excess cash generation. We believe the life sciences tools and diagnostics industry is a “good neighborhood,” characterized by relatively high entry barriers, high customer switching costs and rational competitive behavior. Currency headwinds and investor rotation toward more cyclically- exposed areas of the industrial and healthcare sectors left Thermo’s stock largely unchanged the past 18 months while our estimate of business value grew nicely. We took advantage, initiating a position at, what we believe is, an attractive valuation. Read more...
John Rogers Comments on Thermo Fisher Scientific Inc. Guru stock highlight
Also, scientific research supplier Thermo Fisher Scientific Inc. (NYSE:TMO) dropped –11.20% despite an earnings beat. The company reported earnings per share of $2.03 in late October, well ahead of the $1.97 consensus estimate; it also closed its acquisition of electron microscope maker FEI Company. Health care stocks were generally weak in November and December as investors rotated away from defensive stocks toward more aggressive ones. In our view, the company remains on the right track. Read more...
5 Stocks Hit 52-Week High Prices Thermo Fisher and Goldman Sachs among companies with rising prices
According to GuruFocus' list of 52-week highs, these guru stocks have reached their historical high prices. Read more...

Ratios

vs
industry
vs
history
PE Ratio 30.17
TMO's PE Ratio is ranked higher than
51% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. TMO: 30.17 )
Ranked among companies with meaningful PE Ratio only.
TMO' s PE Ratio Range Over the Past 10 Years
Min: 12.67  Med: 26.53 Max: 62.79
Current: 30.17
12.67
62.79
Forward PE Ratio 18.05
TMO's Forward PE Ratio is ranked higher than
94% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. TMO: 18.05 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.11
TMO's PE Ratio without NRI is ranked higher than
52% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. TMO: 30.11 )
Ranked among companies with meaningful PE Ratio without NRI only.
TMO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.48  Med: 26.58 Max: 62.07
Current: 30.11
13.48
62.07
Price-to-Owner-Earnings 24.54
TMO's Price-to-Owner-Earnings is ranked higher than
62% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. TMO: 24.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TMO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.21  Med: 19.1 Max: 74.79
Current: 24.54
9.21
74.79
PB Ratio 2.97
TMO's PB Ratio is ranked higher than
62% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. TMO: 2.97 )
Ranked among companies with meaningful PB Ratio only.
TMO' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.6 Max: 2.97
Current: 2.97
0.83
2.97
PS Ratio 3.50
TMO's PS Ratio is ranked higher than
51% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. TMO: 3.50 )
Ranked among companies with meaningful PS Ratio only.
TMO' s PS Ratio Range Over the Past 10 Years
Min: 1.25  Med: 2.33 Max: 3.61
Current: 3.5
1.25
3.61
Price-to-Free-Cash-Flow 23.38
TMO's Price-to-Free-Cash-Flow is ranked higher than
51% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. TMO: 23.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TMO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.23  Med: 20.1 Max: 31.02
Current: 23.38
10.23
31.02
Price-to-Operating-Cash-Flow 20.32
TMO's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. TMO: 20.32 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TMO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.74  Med: 17.23 Max: 25.65
Current: 20.32
8.74
25.65
EV-to-EBIT 31.14
TMO's EV-to-EBIT is ranked lower than
67% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. TMO: 31.14 )
Ranked among companies with meaningful EV-to-EBIT only.
TMO' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.9  Med: 23.1 Max: 64.9
Current: 31.14
10.9
64.9
EV-to-EBITDA 18.38
TMO's EV-to-EBITDA is ranked higher than
52% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. TMO: 18.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
TMO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.3 Max: 32.6
Current: 18.38
6.8
32.6
PEG Ratio 2.06
TMO's PEG Ratio is ranked higher than
70% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. TMO: 2.06 )
Ranked among companies with meaningful PEG Ratio only.
TMO' s PEG Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.74 Max: 2.95
Current: 2.06
0.48
2.95
Shiller PE Ratio 45.22
TMO's Shiller PE Ratio is ranked lower than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. TMO: 45.22 )
Ranked among companies with meaningful Shiller PE Ratio only.
TMO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 20.68  Med: 40.48 Max: 62.7
Current: 45.22
20.68
62.7
Current Ratio 1.37
TMO's Current Ratio is ranked lower than
77% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TMO: 1.37 )
Ranked among companies with meaningful Current Ratio only.
TMO' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 2.42 Max: 3.83
Current: 1.37
0.9
3.83
Quick Ratio 0.93
TMO's Quick Ratio is ranked lower than
83% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. TMO: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
TMO' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.85 Max: 3.4
Current: 0.93
0.61
3.4
Days Inventory 81.43
TMO's Days Inventory is ranked higher than
50% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. TMO: 81.43 )
Ranked among companies with meaningful Days Inventory only.
TMO' s Days Inventory Range Over the Past 10 Years
Min: 65.13  Med: 69.62 Max: 81.43
Current: 81.43
65.13
81.43
Days Sales Outstanding 60.30
TMO's Days Sales Outstanding is ranked higher than
53% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. TMO: 60.30 )
Ranked among companies with meaningful Days Sales Outstanding only.
TMO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.89  Med: 53.81 Max: 60.89
Current: 60.3
50.89
60.89
Days Payable 33.75
TMO's Days Payable is ranked lower than
70% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. TMO: 33.75 )
Ranked among companies with meaningful Days Payable only.
TMO' s Days Payable Range Over the Past 10 Years
Min: 31.3  Med: 32.52 Max: 41.58
Current: 33.75
31.3
41.58

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.36
TMO's Dividend Yield % is ranked lower than
89% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. TMO: 0.36 )
Ranked among companies with meaningful Dividend Yield % only.
TMO' s Dividend Yield % Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.86
Current: 0.36
0.22
0.86
Dividend Payout Ratio 0.12
TMO's Dividend Payout Ratio is ranked higher than
93% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. TMO: 0.12 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TMO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.13 Max: 0.17
Current: 0.12
0.12
0.17
Forward Dividend Yield % 0.36
TMO's Forward Dividend Yield % is ranked lower than
91% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. TMO: 0.36 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.36
TMO's 5-Year Yield-on-Cost % is ranked lower than
91% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. TMO: 0.36 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TMO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.22  Med: 0.47 Max: 0.86
Current: 0.36
0.22
0.86
3-Year Average Share Buyback Ratio -3.00
TMO's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. TMO: -3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TMO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.3  Med: -3.8 Max: 4.4
Current: -3
-37.3
4.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.44
TMO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. TMO: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TMO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.65  Med: 1.55 Max: 43.11
Current: 1.44
0.65
43.11
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.32
TMO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
71% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. TMO: 1.32 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.51
TMO's Price-to-Median-PS-Value is ranked lower than
76% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. TMO: 1.51 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TMO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 0.8 Max: 1.52
Current: 1.51
0.24
1.52
Price-to-Peter-Lynch-Fair-Value 2.21
TMO's Price-to-Peter-Lynch-Fair-Value is ranked higher than
67% of the 27 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. TMO: 2.21 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
TMO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.71 Max: 14.2
Current: 2.21
0.59
14.2
Earnings Yield (Greenblatt) % 3.21
TMO's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. TMO: 3.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TMO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.5  Med: 4.3 Max: 9.1
Current: 3.21
1.5
9.1
Forward Rate of Return (Yacktman) % 16.90
TMO's Forward Rate of Return (Yacktman) % is ranked higher than
80% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. TMO: 16.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TMO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 13.5  Med: 21.1 Max: 35.5
Current: 16.9
13.5
35.5

More Statistics

Revenue (TTM) (Mil) $18,744
EPS (TTM) $ 5.48
Beta1.01
Short Percentage of Float1.03%
52-Week Range $139.07 - 168.76
Shares Outstanding (Mil)391.22

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 19,535 20,337 21,085
EPS ($) 8.36 8.72 10.99
EPS without NRI ($) 8.36 8.72 10.99
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.73%
Dividends per Share ($) 0.63 0.69 0.77
» More Articles for NYSE:TMO

Headlines

Articles On GuruFocus.com
New X-ray Machine Handles Heavy Products in Washdown Environments Apr 18 2017 
Just Buy It Mar 27 2017 
Weitz Funds Comments on Thermo Fisher Scientific Jan 26 2017 
John Rogers Comments on Thermo Fisher Scientific Inc. Jan 20 2017 
John Rogers' Ariel Appreciation Fund 4th Quarter Commentary Jan 20 2017 
8 Best Stocks for Value Investors Dec 10 2016 
A Quick Review of Thermo Fisher Dec 07 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
5 Stocks Hit 52-Week High Prices Jul 11 2016 
5 Companies Achieve 52-Week Highs Jun 07 2016 

More From Other Websites
Edited Transcript of TMO earnings conference call or presentation 26-Apr-17 12:30pm GMT Apr 27 2017
Edwards Lifesciencse and Deckers rise; US Steel plunges Apr 26 2017
Thermo Fisher Scientific, Inc. – Value Analysis (NYSE:TMO) : April 26, 2017 Apr 26 2017
GLOBAL MARKETS-Stocks retreat after Trump tax plan; Canada dollar, Mexico peso weaken Apr 26 2017
GLOBAL MARKETS-Stocks advance on earnings; Canada dollar, Mexico peso weaken on NAFTA news Apr 26 2017
Thermo Fisher (TMO) Tops Q1 Earnings, Sales, Raises Guidance Apr 26 2017
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates Apr 26 2017
Thermo Fisher tops profit estimate, ups forecast Apr 26 2017
Thermo Fisher beats Street 1Q forecasts Apr 26 2017
Thermo Fisher Scientific Reports First Quarter 2017 Results Apr 26 2017
Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bullish Manner : TMO-US :... Apr 25 2017
Thermo Fisher (TMO) Up 4.5% Since Earnings Report: Can It Continue? Apr 21 2017
The Top Gene-Sequencing Stock to Buy in 2017 Apr 20 2017
Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings? Apr 20 2017
New X-ray Machine Handles Heavy Products in Washdown Environments Apr 18 2017
ETFs with exposure to Thermo Fisher Scientific, Inc. : April 5, 2017 Apr 05 2017
Thermo Fisher Scientific, Inc. : TMO-US: Dividend Analysis : March 15th, 2017 (record date) : By the... Apr 05 2017
Thermo Fisher CEO got $59M in compensation, stock value in 2016 Apr 04 2017
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 26, 2017 Mar 31 2017
Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bearish Manner : TMO-US :... Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)